Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Inclusion Criteria: * Patients must have histologically or cytologically confirmed head and neck squamous cell carcinoma. * Measurable disease by scans- at least one measurable lesion. * Patients must have received previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy. * Patients must have a Performance Status of 0-2. * Patients must be greater than or equal to 18 years old. * Participant is willing and able to comply with the protocol for the duration of the study. * Ability to understand and the willingness to sign an Institutional Review Board-approved informed consent document. Exclusion Criteria: * Prior treatment with Cetuximab or prior therapy that specifically and directly targets the epidermal growth factor receptor (EGFR) pathway in the last five (5) years. * Prior allergic reaction to Cetuximab. * History of allergic reactions attributed to compounds of chemical or biologic composition similar to those of Cetuximab. * Patients receiving any other investigational agents. * Patient is on medications that need to be continued and that might interact with Cetuximab. * Any uncontrolled condition, which in the opinion of the investigator, would interfere in the safe and timely completion of study treatment and procedures. * Participant with a history of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on screening chest imaging. Any of the following conditions: *…